148 related articles for article (PubMed ID: 33327048)
1. Ovarian cancer risk score predicts chemo-response and outcome in epithelial ovarian carcinoma patients.
Lu HY; Tai YJ; Chen YL; Chiang YC; Hsu HC; Cheng WF
J Gynecol Oncol; 2021 Mar; 32(2):e18. PubMed ID: 33327048
[TBL] [Abstract][Full Text] [Related]
2. Dysregulation of lnc-SNHG1 and miR-216b-5p correlate with chemoresistance and indicate poor prognosis of serous epithelial ovarian cancer.
Pei ML; Zhao ZX; Shuang T
J Ovarian Res; 2020 Dec; 13(1):144. PubMed ID: 33302997
[TBL] [Abstract][Full Text] [Related]
3. Low expression of NCALD is associated with chemotherapy resistance and poor prognosis in epithelial ovarian cancer.
Feng LY; Li L
J Ovarian Res; 2020 Mar; 13(1):35. PubMed ID: 32228639
[TBL] [Abstract][Full Text] [Related]
4. [Bioinformatics analysis of drug-resistant ceRNA in epithelial ovarian cancer].
Pan ZM; Tan FC; Chen CX; Zhang W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2021 Feb; 56(2):121-130. PubMed ID: 33631884
[No Abstract] [Full Text] [Related]
5. Gene expression patterns of chemoresistant and chemosensitive serous epithelial ovarian tumors with possible predictive value in response to initial chemotherapy.
Bachvarov D; L'esperance S; Popa I; Bachvarova M; Plante M; Têtu B
Int J Oncol; 2006 Oct; 29(4):919-33. PubMed ID: 16964388
[TBL] [Abstract][Full Text] [Related]
6. Helicase POLQ-like (HELQ) as a novel indicator of platinum-based chemoresistance for epithelial ovarian cancer.
Long J; Zhu JY; Liu YB; Fu K; Tian Y; Li PY; Yang WQ; Yang SY; Yin JY; Yin G; Zhang Y
Gynecol Oncol; 2018 May; 149(2):341-349. PubMed ID: 29572031
[TBL] [Abstract][Full Text] [Related]
7. Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base.
Canaz E; Grabowski JP; Richter R; Braicu EI; Chekerov R; Sehouli J
Gynecol Oncol; 2019 Sep; 154(3):539-546. PubMed ID: 31230821
[TBL] [Abstract][Full Text] [Related]
8. [Analysis of factors related to the prognostic benefit of neoadjuvant chemotherapy followed by interval debulking surgery in patients with advanced ovarian cancer].
Wang DF; Zhang GN; Peng CR; Shi Y; Shi XW
Zhonghua Fu Chan Ke Za Zhi; 2021 Jun; 56(6):385-392. PubMed ID: 34154313
[No Abstract] [Full Text] [Related]
9. Genetic variants and expression of the TIM-3 gene are associated with clinical prognosis in patients with epithelial ovarian cancer.
Wu JL; Zhao J; Zhang HB; Zuo WW; Li Y; Kang S
Gynecol Oncol; 2020 Oct; 159(1):270-276. PubMed ID: 32694063
[TBL] [Abstract][Full Text] [Related]
10. Multi-omics analysis of tumor mutational burden combined with prognostic assessment in epithelial ovarian cancer based on TCGA database.
Liu J; Xu W; Li S; Sun R; Cheng W
Int J Med Sci; 2020; 17(18):3200-3213. PubMed ID: 33173439
[No Abstract] [Full Text] [Related]
11. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.
Muraji M; Sudo T; Iwasaki S; Ueno S; Wakahashi S; Yamaguchi S; Fujiwara K; Nishimura R
Gynecol Oncol; 2013 Dec; 131(3):531-4. PubMed ID: 24096109
[TBL] [Abstract][Full Text] [Related]
12. Over-expression of Sirt1 contributes to chemoresistance and indicates poor prognosis in serous epithelial ovarian cancer (EOC).
Shuang T; Wang M; Zhou Y; Shi C
Med Oncol; 2015 Dec; 32(12):260. PubMed ID: 26520143
[TBL] [Abstract][Full Text] [Related]
13. Over-expression of nuclear NF-κB1 and c-Rel correlates with chemoresistance and prognosis of serous epithelial ovarian cancer.
Shuang T; Wang M; Zhou Y; Shi C
Exp Mol Pathol; 2016 Feb; 100(1):139-44. PubMed ID: 26683819
[TBL] [Abstract][Full Text] [Related]
14. A TGF-β associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian cancer.
Gagno S; Poletto E; Bartoletti M; Quartuccio L; Romualdi C; Garziera M; Scalone S; Sorio R; Dreussi E; Zanusso C; De Mattia E; Roncato R; Cecchin E; Giorda G; De Vita S; Dal Bo M; Puglisi F; Toffoli G
Gynecol Oncol; 2020 Jan; 156(1):233-242. PubMed ID: 31711657
[TBL] [Abstract][Full Text] [Related]
15. TP53 K351N mutation-associated platinum resistance after neoadjuvant chemotherapy in patients with advanced ovarian cancer.
Zhang GN; Liu H; Huang JM; Wang L; Zhao JS; Li C; Mi K; Zhu Y; Cheng J; Zha X
Gynecol Oncol; 2014 Mar; 132(3):752-7. PubMed ID: 24463159
[TBL] [Abstract][Full Text] [Related]
16. Predictive biomarkers of platinum and taxane resistance using the transcriptomic data of 1816 ovarian cancer patients.
Fekete JT; Ősz Á; Pete I; Nagy GR; Vereczkey I; Győrffy B
Gynecol Oncol; 2020 Mar; 156(3):654-661. PubMed ID: 31973910
[TBL] [Abstract][Full Text] [Related]
17. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of CHI3L1 is associated with chemoresistance and poor outcome of epithelial ovarian carcinoma.
Chiang YC; Lin HW; Chang CF; Chang MC; Fu CF; Chen TC; Hsieh SF; Chen CA; Cheng WF
Oncotarget; 2015 Nov; 6(37):39740-55. PubMed ID: 26452028
[TBL] [Abstract][Full Text] [Related]
19. Specific point mutations in key redox enzymes are associated with chemoresistance in epithelial ovarian cancer.
Fletcher NM; Belotte J; Saed MG; Memaj I; Diamond MP; Morris RT; Saed GM
Free Radic Biol Med; 2017 Jan; 102():122-132. PubMed ID: 27890641
[TBL] [Abstract][Full Text] [Related]
20. Nuclear orphan receptor NR2F6 confers cisplatin resistance in epithelial ovarian cancer cells by activating the Notch3 signaling pathway.
Li H; Zhang W; Niu C; Lin C; Wu X; Jian Y; Li Y; Ye L; Dai Y; Ouyang Y; Chen J; Qiu J; Song L; Zhang Y
Int J Cancer; 2019 Oct; 145(7):1921-1934. PubMed ID: 30895619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
